Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505
1996

Induction of Apoptosis in Cancer Cells by NU/ICRF 505

publication Evidence: moderate

Author Information

Author(s): I Meikle, J Cummings, JS Macpherson, JF Smyth

Primary Institution: Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh EH4 2XU, UK.

Hypothesis

Can the anthracenyl-amino acid conjugate NU/ICRF 505 induce apoptosis in human cancer cell lines?

Conclusion

NU/ICRF 505 induces apoptosis in HL60 cells and shows potential cytotoxic effects in other cancer cell lines.

Supporting Evidence

  • NU/ICRF 505 induced a substantial increase in DNA fragmentation in HL60 cells after 48 and 72 hours.
  • Co-treatment with zinc reduced DNA fragmentation in HL60 cells treated with NU/ICRF 505.
  • Similar effects of NU/ICRF 505 were observed in human lung (NX002) and ovarian (A2780) cancer cell lines.

Takeaway

A new drug called NU/ICRF 505 can help cancer cells die by making their DNA break apart, which is a sign of a process called apoptosis.

Methodology

The study used endonucleolytic DNA cleavage as a marker of apoptosis and assessed DNA fragmentation in various human cancer cell lines after treatment with NU/ICRF 505.

Limitations

The study did not explore the long-term effects of NU/ICRF 505 on all cancer cell lines and the exact mechanisms of cell death remain unclear.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication